Inside NEU: The ASX pharma star with a long runway for growth
Rask Australia
October 22, 2025
Discover why Neuren Pharmaceuticals (ASX:NEU) is seen as a rising
Discover why Neuren Pharmaceuticals (ASX:NEU) is seen as a rising
S&P 500 and Nasdaq rebound 9% and 11% respectively. Australian
Here’s today’s The Match Out report from Market Matters’ James
Here’s today’s The Match Out report from Market Matters’ James
Australia’s share market pushed higher on Wednesday, as the big
Here’s today’s The Match Out report from Market Matters’ James
At the $240 million Perennial Better Future Trust, healthcare stocks
Here’s today’s The Match Out report from Market Matters’ James
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.